Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Moderate Buy” by Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $11.13.

STRO has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a report on Monday, November 18th. Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Sutro Biopharma in a research note on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a report on Wednesday, December 11th. Finally, Wells Fargo & Company reduced their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th.

Hedge Funds Weigh In On Sutro Biopharma

Several large investors have recently modified their holdings of STRO. Suvretta Capital Management LLC lifted its position in Sutro Biopharma by 3.8% in the fourth quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company’s stock worth $13,731,000 after buying an additional 275,000 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Sutro Biopharma in the 4th quarter worth about $4,729,000. Geode Capital Management LLC boosted its stake in shares of Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after purchasing an additional 132,015 shares during the period. Parkman Healthcare Partners LLC boosted its stake in shares of Sutro Biopharma by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company’s stock worth $3,179,000 after purchasing an additional 11,793 shares during the period. Finally, State Street Corp grew its holdings in Sutro Biopharma by 5.2% during the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company’s stock valued at $5,699,000 after purchasing an additional 81,855 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 4.7 %

NASDAQ STRO opened at $1.34 on Friday. Sutro Biopharma has a twelve month low of $1.26 and a twelve month high of $6.13. The business has a 50-day moving average price of $1.80 and a 200-day moving average price of $2.80. The firm has a market cap of $110.50 million, a price-to-earnings ratio of -0.83 and a beta of 1.22.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.